Currently out of the existing stock ratings of Matthew Harrison, 359 are a HOLD (34.55%), 593 are a BUY (57.07%), 87 are a SELL (8.37%).

Matthew Harrison

Work Performance Price Targets & Ratings Chart

Analyst Matthew Harrison, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 63.82% that have a potential upside of 30.39% achieved within 309 days.

Matthew Harrison’s has documented 2,115 price targets and ratings displayed on 101 stocks. The coverage is on Healthcare, Technology, Basic Materials, Energy, Industrials, Consumer Cyclical sectors.

Most recent stock forecast was given on R, Ryder System at 24-Jul-2026.

Wall Street Analyst Matthew Harrison

Analyst best performing recommendations are on CMRX (CHIMERIX).
The best stock recommendation documented was for CMRX (CHIMERIX) at 2/23/2016. The price target of $5 was fulfilled within 1 day with a profit of $0.54 (12.11%) receiving and performance score of 121.08.

Average potential price target upside

of $269.48 (87.58%) on ALVR (ALLOVIR ).
of $165.8 (76.65%) on DBVT (DBV TECHNOLOGIES).
of $95.89 (15.11%) on REGN (REGENERON PHARMACEUTICALS).

ADCT ADC Therapeutics SA ADGI Adagio Therapeutics ALVR Allovir ALXN Alexion Pharmaceuticals AMGN Amgen ARGX argenx NV ADR AVIR Atea Pharmaceuticals BGNE BeiGene Ltd BHVN Biohaven Pharmaceutical Holding Co Ltd BIIB Biogen BLUE Bluebird bio BMRN Biomarin Pharmaceutical BMY Bristol-Myers Squibb Company BNTX BioNTech SE CCMP CMC Materials CELG Celgene DNLI Denali Therapeutics EVLO Evelo Biosciences FULC Fulcrum Therapeutics FUSN Fusion Pharmaceuticals GBT Global Blood Therapeutics GLPG Galapagos NV ADR HUN Huntsman IMGN ImmunoGen INSM Insmed KLDO Kaleido Biosciences KOD Kodiak Sciences LEGN Legend Biotech Corp MRK Merck mpany MRNA Moderna PFE Pfizer PTLA Portola Pharmaceuticals REGN Regeneron Pharmaceuticals RPM RPM International SGEN Seagen SGTX Sigilon Therapeutics SRPT Sarepta Therapeutics VRTX Vertex Pharmaceuticals VVV Valvoline ABBV AbbVie GILD Gilead Sciences JNJ Johnson & Johnson RDUS Schnitzer Steel Industries SAGE Sage Therapeutic ALNY Alnylam Pharmaceuticals CERE Cerevel Therapeutics Holdings CNTA Centessa Pharmaceuticals PLC ADR EDIT Editas Medicine FUL H B Fuller Company GMAB Genmab AS IMMU Immunomedics IMRA Imara LLY Eli Lilly and Company RGNX Regenxbio TSVT 2Seventy Bio ADAG Adagene AKRO Akero Therapeutics BOLT Bolt Biotherapeutics PHVS Pharvaris BV VACC XLRN Acceleron Pharma ALEC Alector CABA Cabaletta Bio CYTK Cytokinetics INCY yte RUBY Rubius Therapeutics ZNTL Zentalis Pharmaceuticals Llc SANA Sana Biotechnology TNYA Tenaya Therapeutics APD Air Products and Chemicals AXTA Axalta Coating Systems Ltd CMRX Chimerix ENTG Entegris FTSV Forty Seven GRA W. R. Grace INVA Innoviva IOBT IO Biotech IVVD Invivyd KOP Koppers Holdings KWR Quaker Chemical LYEL Lyell Immunopharma MTX Minerals Technologies SHW Sherwin-Williams Co UBX Unity Biotechnology VIGL Vigil Neuroscience DBVT DBV Technologies LIN Linde plc Ordinary Shares FMC FMC AVNT Avient Corp TSHA Taysha Gene Therapies PRME Prime Medicine, Common Stock COGT Cogent Biosciences R Ryder System AL Air Lease ALV Autoliv BL Blackline CE Celanese SA Seabridge Gold SG Sweetgreen TS Tenaris SA ADR VYGR Voyager Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Robert Burns (HC WAINWRIGHT)